Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: A randomized controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 8, 2012, Pages 2799-2808

  Dempster, David W ^a   Zhou, Hua ^a   Recker, Robert R ^b   Brown, Jacques P ^c   Bolognese, Michael A ^d   Recknor, Christopher P ^e   Kendler, David L ^f   Lewiecki, E Michael ^g   Hanley, David A ^h   Rao, D Sudhaker ⁱ   Miller, Paul D ^j   Woodson III, Grattan C ^k   Lindsay, Robert ^a   Binkley, Neil ^l   Wan, Xiaohai ^m   Ruff, Valerie A ^m   Janos, Boris ⁿ   Taylor, Kathleen A ^m  

^a HELEN HAYES HOSPITAL   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ LAVAL   (Canada)

^d Bethesda Health Research   (United States)

^e United Osteoporosis Centers   (United States)

^f Prohealth Clinical Research   (Canada)

^g NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^h ALBERTA ENVIRONMENT AND PARKS   (Canada)

ⁱ HENRY FORD HOSPITAL   (United States)

^j Health Sciences Center and Colorado Center for Bone Research   (United States)

^k Atlanta Research Center   (United States)

^l UNIVERSITY OF WISCONSIN MADISON   (United States)

^m Lilly USA   (United States)

ⁿ ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BONE BIOPSY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CANADA; CHILL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEMATOMA; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MINERAL APPOSITION RATE; MINERALIZING SURFACE BONE SURFACE; MORPHOMETRICS; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL SYSTEM PARAMETERS; NAUSEA; PAIN; PHASE 4 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UNITED STATES; VITAL SIGN; VOMITING;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOGENESIS; TERIPARATIDE;

EID: 84864796286     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1262     Document Type: Article

References (21)

1. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610
2. Hernandez CJ, Beaupré GS, Marcus R, Carter DR 2001 A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 29:511-516 (Pubitemid 33124292)
3. Riggs BL, Parfitt AM 2005 Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 20:177-184
4. Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB 2011 Issues in modern bone histomorphometry. Bone 49:955-964
5. Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625 (Pubitemid 35449706)
6. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewicki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF 2008 Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16
7. Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW 2010 Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25:2256-2265
8. Foldes J, Shih MS, Parfitt AM 1990 Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res 5:1063-1067 (Pubitemid 20371552)
9. Hauge E, Mosekilde L, Melsen F 1999 Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone 25:389-395 (Pubitemid 29424231)
10. Ebeling PR, Burr DB 2008 Positive effects of intravenous zoledronic acid on bone remodeling and structure: are different effects on osteoblast activity to other oral bisphosphonates responsible? J Bone Miner Res 23:2-5
11. Compston JE 2008 Zoledronic acid-does it have anabolic as well as antiresorptive effects? IBMS Bone KEy 5:103-107
12. Rao DS 1983 Practical approach to bone biopsy. In: RR Recker, ed. Bone histomorphometry: techniques and interpretation. Boca Raton, FL: CRC Press; 3
13. Dempster DW, Shane ES 1995 Bone quantification and dynamics of bone turnover by histomorphometric analysis. In: KL Becker, ed. Principles and practice of endocrinology and metabolism. 2nd edition. Philadelphia: J. B. Lippincott Co.; 491-498
14. Duncan H 1973 Cortical porosis: a morphological evaluation. In: Jaworski ZFG, ed. Proceedings of the first workshop in bone morphometry. Ottawa, Canada: University of Ottawa Press; 78
15. Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J 2009 Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24:1358-1368
16. Jiang Y, Zhao JJ, Mitlak BH,Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18:1932-1941 (Pubitemid 37377441)
17. Ma YL, Zeng Q, Donley DW, Ste. Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF 2006 Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 21:855-864 (Pubitemid 43787992)
18. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480 (Pubitemid 27425772)
19. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694
20. Arlot M, Meunier PJ, Boivin G, Haddock L, Tamayo J, Correa-Rotter R, Jasqui S, Donley DW, Dalsky GP, San Martin JS, Eriksen EF 2005 Differential effects of teriparatide and alendronate on bone remodeling in postmenopsausal women assessed by histomorphometric parameters. J Bone Miner Res 20:1244-1253 (Pubitemid 40863814)
21. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768 (Pubitemid 41138965)